| Message: | Semaglutide is a Glucagon-like Peptide-1 (GLP-1) Receptor Agonist. Its activity is similar to that of GLP-1, and it has a high degree affinity with GLP-1 receptor. It can simulate the natural gastrointestinal hormones in human body to promote insulin secretion and regulate blood sugar.
Its clinical data shows that Semaglutide has a significant effect on the treatment of type 2 diabetes, and it was approved by FDA for subcutaneous injection in December 2017 and oral administration in September 2019.
GLP receptor agonists that currently approved on the market include Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide. But these drugs are overdependent on injection administration, there are still major limitations in use for diabetes patients. The way of oral administration fills the gap well. url:http://www.gtpeptide.com |
my account